AACR 2018: Crizotinib yielded a high objective response rate for adult patients with ALK-positive inflammatory myofibroblastic tumour
Among patients with inoperable, advanced, or metastatic ALK-positive inflammatory myofibroblastic tumour, 50 percent were confirmed…